TORONTO–(BUSINESS WIRE)– #FSDDF–FSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE.CN) (FRA: 0K9A) (“FSD Pharma” or the “Company”) today reported that management’s discussion and analysis of financial condition and results of operations (“MD&A”) for the three months ended March 31, 2020 have been filed and can be viewed on the Company’s SEDAR profile at FSD also provided an update on its primary business efforts: The Phase 1 first-in-human safety and tolerability study with ultra micro-palm